The Globe and Mail reports in its Wednesday, Aug. 10, edition that National Bank Financial analyst Endri Leno, ahead of the Aug. 10 release of Dialogue Health Technologies' second quarter results, trimmed his share target to $8.50 from $11.50. The Globe's David Leeder writes in the Eye On Equities column that Mr. Leno continues to rate Dialogue Health "outperform." Analysts on average target the shares at $7.39. Mr. Leno says in a note: "We maintain a positive view on Dialogue Health Technologies due to its 1) top-line visibility through recurring and reoccurring revenues; 2) significant market position in Canadian virtual primary health and mental care; 3) potential to disrupt the in-person primary/mental healthcare and EAP delivery; 4) expectations of continued growth; and 5) the integrated and well-liked approach / platform / user experience. While we remain positive on Dialogue Health and its outlook, the higher interest rate environment leads us to increase our DCF discount rate to 12 per cent (was 10 per cent) resulting in a target of $8.50."